CIK 0000886163
- Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 770160744
- Phone
- +1 858-550-7500
- Business address
- 7111 FAIRWAY DRIVE, SUITE 302, PALM BEACH GARDENS, FL, 33418
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,384,247
- in 9 filings, $4.7M under 10b5-1 plans
Net −$7,384,247. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-02-14 | FOEHR MATTHEW W EVP and COO | Exercise or conversion | +22,500 | $9.97 | $224K | 75,957 |
| 2014-02-14 | FOEHR MATTHEW W EVP and COO | Sale | −22,500 | $79.54 | $1.8M | 53,457 |
| 2014-02-14 | FOEHR MATTHEW W EVP and COO | Exercise or conversion · Employee Stock Option (right to buy) | −3,444 | 155,556 | ||
| 2014-02-14 | FOEHR MATTHEW W EVP and COO | Exercise or conversion · Employee Stock Option (right to buy) | −22,500 | 133,056 | ||
| 2014-02-13 | Aryeh Jason Director | Sale | −6,700 | $77.43 | $519K | 254,216 |
| 2014-02-13 | Berkman Charles S VP, Gen. Counsel & Secretary | Exercise or conversion | +2,000 | $14.47 | $29K | 31,645 |
| 2014-02-13 | Berkman Charles S VP, Gen. Counsel & Secretary | Exercise or conversion · Incentive Stock Option (right to buy) | −2,000 | 13,130 | ||
| 2014-02-12 | Aryeh Jason Director | Sale | −24,120 | $75.21 | $1.8M | 260,916 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +1,166 | $21.00 | $24K | 18,833 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −1,166 | $74.27 | $87K | 17,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +16,666 | $16.14 | $269K | 34,333 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −16,666 | $74.27 | $1.2M | 17,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +1,000 | $16.14 | $16K | 18,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −1,000 | $74.27 | $74K | 17,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +8,333 | $40.86 | $340K | 26,000 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −8,333 | $75.73 | $631K | 17,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +7,321 | $21.00 | $154K | 24,988 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −7,321 | $74.27 | $544K | 17,667 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Exercise or conversion | +6,012 | $21.00 | $126K | 23,679 |
| 2014-02-12 | Sharp John P VP Finance and CFO | Sale | −6,012 | $75.73 | $455K | 17,667 |
Page 76 of 86 · 1,712 trades